Skip to content

Twitter page opens in new window Linkedin page opens in new window Instagram page opens in new window

info@pharmaust.com+61 8 9202 6814

PharmAust (PAA)

HOME
ABOUT
PIPELINE & TRIALS
INVESTOR CENTRE
MEDIA
CONTACT

HOME
ABOUT
PIPELINE & TRIALS
INVESTOR CENTRE
MEDIA
CONTACT

October 31, Top 20 Shareholders

201031_Top_Holders_Report (87)

Categories: News & Announcements 2020, Top 20 ShareholdersBy Richard Mollard November 2, 2020

Related posts

February 28, Top 20 Shareholders
March 1, 2021

January 31, Top 20 Shareholders
February 1, 2021

December 31, Top 20 Shareholders
January 4, 2021

December 23, PharmAust Commences MPL Manufacture for Human Clinical Trials
December 23, 2020

December 22, PharmAust Set to Commence Phase IIb Anticancer Canine Trial
December 22, 2020

December 21, Epichem Awarded DNDi Extension
December 21, 2020

Recent Articles

February 28, Top 20 Shareholders
March 1, 2021
February 15, Canine Monepantel Phase IIb Lymphoma Trial Update
February 14, 2021
February 10, LUMC Covid-19 Research Update
February 10, 2021
January 31, Top 20 Shareholders
February 1, 2021

MENU

Home
About Us
Pipeline & Trials
Investor Centre
Media
Contact Us

SUBSCRIBE TO OUR NEWSLETTER

Leave this field empty if you're human:

TWITTER

PharmAustFollow

PharmAust @PharmAust·

PharmAust is currently recruiting dogs with B cell lymphoma for a Phase IIb clinical trial with a non-toxic anti cancer drug

Click below to watch $PAA Executive Chairman Dr Roger Aston interviewed by @alanamclean_ on @tickerNEWSau

https://tickernews.co/programs/roger-aston-anti-cancer-drug-for-dogsmp4-8598c1

Reply on Twitter 1365081126042132480 Retweet on Twitter 1365081126042132480 Like on Twitter 13650811260421324802 Twitter 1365081126042132480

Copyright © 2020 Pharmaust. All rights reserved.

Website Design & Digital Marketing Perth by Total Click Solutions